{"id":157745,"date":"2026-11-09T14:58:12","date_gmt":"2026-11-09T14:58:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/157745\/"},"modified":"2026-11-09T14:58:12","modified_gmt":"2026-11-09T14:58:12","slug":"pharmalittle-novartis-abandons-heart-drug-bio-fights-medicare-pilot","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/157745\/","title":{"rendered":"Pharmalittle: Novartis abandons heart drug, BIO fights Medicare pilot"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the usual routine of online meetings, phone calls, and deadlines has returned. You knew this would happen, yes? So to cope, we are firing up the trusty kettle and brewing another cuppa stimulation. Our choice today is blueberry hibiscus \u2014 with a dollop of bourbon honey. Please feel free to join us. Or grab a bottle of water, if you prefer. Meanwhile, we have assembled the latest line-up of interesting items for you to peruse. We hope your journey today is meaningful and productive. And as always, please keep in touch. Your tips and insights help the world go around. \u2026<\/p>\n<p class=\"wp-block-paragraph\">Novartis is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths, <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-11-07\/novartis-abandons-heart-drug-after-surprising-failure-in-key-study\" id=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-11-07\/novartis-abandons-heart-drug-after-surprising-failure-in-key-study\" target=\"_blank\" rel=\"noopener nofollow\">Bloomberg News<\/a> notes. The move came as details of a key Novartis study were presented at the American Heart Association meeting this weekend. The growing field of research aimed at lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, took a hit earlier this year when top-line Novartis results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes.\u00a0Other drugmakers pursuing Lp(a) drugs include Amgen, Eli Lilly, and Silence Therapeutics, <a href=\"https:\/\/www.statnews.com\/2026\/11\/07\/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery\/\" id=\"https:\/\/www.statnews.com\/2026\/11\/07\/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery\/\" rel=\"nofollow noopener\" target=\"_blank\">STAT<\/a> adds.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">The Biotechnology Innovation Organization is joining the legal fight against a Trump administration pilot program aimed at aligning drug prices in Medicare with prices charged in peer countries, <a href=\"https:\/\/www.statnews.com\/2026\/11\/07\/bio-sues-to-block-globe-drug-pricing-model\/\" id=\"https:\/\/www.statnews.com\/2026\/11\/07\/bio-sues-to-block-globe-drug-pricing-model\/\" rel=\"nofollow noopener\" target=\"_blank\">STAT<\/a> says. BIO and two California-based biotech trade groups filed a\u00a0<a href=\"https:\/\/www.bio.org\/sites\/default\/files\/2026-11\/n.d._cal._26-cv-13372_dckt_000001_000_filed_2026-11-06.pdf\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">complaint<\/a>\u00a0in the U.S. District Court for the Northern District of California asserting the\u00a0<a href=\"https:\/\/public-inspection.federalregister.gov\/2026-20281.pdf\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Global Benchmark for Efficient Drug Pricing<\/a>\u00a0demonstration, known as GLOBE, oversteps Medicare\u2019s statutory authority. The complaint seeks to halt the model. GLOBE, which applies to Medicare Part B drugs administered in doctor offices,\u00a0is not expected to have much impact because the administration exempted all but a handful of companies in return for their agreement to voluntary deals to charge Medicaid most-favored-nation prices.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/1794236292_94_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,&hellip;\n","protected":false},"author":2,"featured_media":157746,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,30229,339],"class_list":["post-157745","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-pharmalittle","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117587077135757809","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=157745"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157745\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/157746"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=157745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=157745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=157745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}